Biodesix (NASDAQ: BDSX) grants CCO 27,000 stock options at $6.46

Rhea-AI Filing Summary

Biodesix Inc. reported an insider stock option grant to its Chief Commercial Officer, Kieran O'Kane. On January 2, 2026, O'Kane was awarded stock options representing the right to buy 27,000 shares of Biodesix common stock at an exercise price of $6.46 per share. These options were granted at no cost to him and are held directly.

The option grant has a long-term structure. It vests in forty-eight substantially equal monthly installments starting January 2, 2026, generally requiring O'Kane to continue serving at the company through each vesting date. The options are scheduled to expire on January 1, 2036 if not exercised.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Kane Kieran

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$6.46	01/02/2026		A		27,000		(1)	01/01/2036	Common Stock	27,000	$0	27,000	D

Explanation of Responses:

1. This option vests in a series of forty-eight successive, substantially equal monthly installments measured from January 2, 2026, generally subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biodesix (BDSX) disclose in this Form 4?

Biodesix disclosed that Chief Commercial Officer Kieran O'Kane received stock options to purchase 27,000 shares of Biodesix common stock on January 2, 2026.

What is Kieran O'Kane's role at Biodesix (BDSX)?

Kieran O'Kane is reported as an officer of Biodesix, serving as the company's Chief Commercial Officer.

What is the exercise price and size of the Biodesix stock option grant?

The derivative security is Stock Options (Right to Buy) covering 27,000 shares of common stock with a $6.46 exercise price per share.

How do the Biodesix options granted to Kieran O'Kane vest?

According to the footnote, the option vests in a series of forty-eight successive, substantially equal monthly installments starting from January 2, 2026, generally subject to O'Kane's continued service through each vesting date.

When do Kieran O'Kane's Biodesix stock options expire?

The stock options granted on January 2, 2026 have an expiration date of January 1, 2036, if they are not exercised before that date.

Is this Biodesix Form 4 filed by more than one reporting person?

No. The filing indicates it is a Form filed by one reporting person, covering transactions by Kieran O'Kane only.

Are the Biodesix stock options held directly or indirectly by Kieran O'Kane?

The filing lists the ownership form as Direct (D), indicating the 27,000 stock options are held directly by Kieran O'Kane.